Market Summary
USD42.48-0.06
Market Closed-0.14%
IONS Stock Price
IONS RSI Chart
IONS Valuation
IONS Price/Sales (Trailing)
IONS Profitability
IONS Fundamentals
IONS Revenue
IONS Earnings
Price Action
52 Week Range
47.74
(Low)(High)
Last 7 days
-1.4%
Last 30 days
8.5%
Last 90 days
3.3%
Trailing 12 Months
-8.5%
IONS Financial Health
IONS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for IONS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-31 | Geary Richard S | acquired | 30.5575 | 30.5575 | 1.00 | officer level 14 |
2023-08-31 | Monia Brett P | acquired | 4,797 | 30.5575 | 157 | ceo level 15 |
2023-08-31 | BENNETT C FRANK | acquired | 5,500 | 30.5575 | 180 | officer level 14 |
2023-08-01 | Diaz Allene M. | sold | -26,969 | 41.05 | -657 | - |
2023-07-18 | KLEIN JOSEPH III | sold | -149,310 | 42.00 | -3,555 | - |
2023-07-17 | BERTHELSEN SPENCER R | acquired | - | - | 7,110 | - |
2023-07-17 | Hayden Michael R | acquired | - | - | 7,110 | - |
2023-07-17 | Diaz Allene M. | acquired | - | - | 5,333 | - |
2023-07-17 | LOSCALZO JOSEPH | acquired | - | - | 7,110 | - |
2023-07-17 | KLEIN JOSEPH III | acquired | - | - | 7,110 | - |
Which funds bought or sold IONS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 58.33 | 4,559 | 10,134 | -% |
2023-09-06 | Deep Track Capital, LP | unchanged | - | 14,992,200 | 116,282,000 | 5.38% |
2023-08-24 | Alberta Investment Management Corp | sold off | -100 | -3,624,960 | - | -% |
2023-08-23 | Stonebridge Capital Advisors LLC | new | - | 2,831 | 2,831 | -% |
2023-08-22 | COMERICA BANK | new | - | 6,000 | 6,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 51.09 | 601,192 | 1,419,640 | 0.01% |
2023-08-21 | BOKF, NA | reduced | -2.51 | 256,784 | 2,410,510 | 0.05% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.53 | 702,215 | 6,605,750 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -8.12 | 18,593 | 359,559 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 8.79 | 2,792,740 | 14,009,700 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Ionis Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 09, 2023 | vanguard group inc | 10.07% | 14,414,917 | SC 13G/A | |
| Feb 14, 2023 | bb biotech ag | 6.8% | 9,635,000 | SC 13G/A | |
| Feb 14, 2023 | t. rowe price investment management, inc. | 8.2% | 11,678,259 | SC 13G | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.54% | 13,546,694 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.5% | 9,182,911 | SC 13G/A | |
| Apr 11, 2022 | price t rowe associates inc /md/ | 10.1% | 14,350,460 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 8.8% | 12,490,280 | SC 13G/A | |
| Feb 11, 2022 | bb biotech ag | 7.2% | 10,232,973 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 8.50% | 12,007,076 | SC 13G/A |
Recent SEC filings of Ionis Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 23, 2023 | 8-K | Current Report | |
| Aug 22, 2023 | 8-K | Current Report | |
| Aug 14, 2023 | 144/A | 144/A | |
| Aug 11, 2023 | S-8 | Employee Benefits Plan | |
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 10-Q | Quarterly Report | |
| Aug 04, 2023 | 8-K | Current Report |
Peers (Alternatives to Ionis Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
Ionis Pharmaceuticals News
Returns for IONS
Cumulative Returns on IONS
2.7%
7-Year Cumulative Returns
-2.8%
5-Year Cumulative Returns
-6.1%
3-Year Cumulative Returns
Risks for IONS
What is the probability of a big loss on IONS?
90%
Probability that Ionis Pharmaceuticals stock will be more than 20% underwater in next one year
55%
Probability that Ionis Pharmaceuticals stock will be more than 30% underwater in next one year.
21.1%
Probability that Ionis Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IONS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Ionis Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Ionis Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 9.5% | 630,591,000 | 575,971,000 | 587,367,000 | 875,483,000 | 848,809,000 | 840,768,000 | 810,456,000 | 660,731,000 | 687,717,000 | 707,504,000 | 729,264,000 | 932,664,000 | 940,477,000 | 958,753,000 | 1,122,599,000 | 821,034,000 | 798,537,000 | 752,471,000 | 599,674,000 | 579,860,000 | 552,779,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 661,046,000 | 653,707,000 | 596,742,000 |
| S&GA Expenses | 7.6% | 174,024,000 | 161,684,000 | 150,295,000 | 139,945,000 | 136,622,000 | 159,275,000 | 186,347,000 | 287,614,000 | 324,968,000 | 340,528,000 | 354,322,000 | 298,732,000 | 290,321,000 | 293,417,000 | 286,644,000 | 269,427,000 | 278,103,000 | 269,190,000 | 244,622,000 | 224,269,000 | 182,345,000 |
| EBITDA | 100.0% | - | -286,018,000 | -235,535,000 | 35,013,000 | -1,953,000 | 20,852,000 | -4,312,000 | -208,291,000 | -156,341,000 | -126,141,000 | -89,562,000 | 130,718,000 | 175,359,000 | 203,257,000 | 387,534,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.50 | -0.40 | 0.04 | 0.00 | 0.02 | -0.01 | -0.32 | -0.23 | -0.18 | -0.12 | 0.14 | 0.19 | 0.21 | 0.35 | - | - | - | - | - | - |
| Interest Expenses | 2.1% | 7,769,000 | 7,608,000 | 8,122,000 | 8,629,000 | 8,830,000 | 9,057,000 | 9,349,000 | 9,545,000 | 9,633,000 | 9,717,000 | 9,510,000 | -15,888,000 | -6,314,000 | 3,047,000 | 12,440,000 | 46,860,000 | 46,140,000 | 45,451,000 | 44,789,000 | 44,119,000 | 43,662,000 |
| Earnings Before Taxes | 8.3% | -281,430,000 | -306,857,000 | -257,985,000 | 11,261,000 | -25,803,000 | -3,476,000 | -29,148,000 | -268,633,000 | -216,410,000 | -171,338,000 | -134,552,000 | 110,278,000 | 145,345,000 | 163,882,000 | 338,766,000 | 119,276,000 | 95,846,000 | 56,573,000 | -76,156,000 | -103,253,000 | -89,872,000 |
| EBT Margin | 100.0% | - | -0.53 | -0.44 | 0.01 | -0.03 | 0.00 | -0.04 | -0.41 | -0.31 | -0.24 | -0.18 | 0.12 | 0.15 | 0.17 | 0.30 | - | - | - | - | - | - |
| Net Income | 6.0% | -309,035,000 | -328,880,000 | -269,722,000 | 7,321,000 | -28,153,000 | -3,893,000 | -28,597,000 | -607,742,000 | -549,743,000 | -494,504,000 | -444,263,000 | 94,684,000 | 145,314,000 | 170,074,000 | 294,145,000 | 429,808,000 | 399,086,000 | 359,604,000 | 273,741,000 | -49,259,000 | -47,311,000 |
| Net Income Margin | 100.0% | - | -0.57 | -0.46 | 0.01 | -0.03 | 0.00 | -0.04 | -0.92 | -0.81 | -0.72 | -0.64 | 0.08 | 0.14 | 0.17 | 0.26 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -400,200,000 | -290,091,000 | 115,428,000 | 86,502,000 | 40,923,000 | 18,844,000 | -89,513,000 | -52,684,000 | -38,998,000 | 772,000 | 178,114,000 | 171,476,000 | 193,675,000 | 314,815,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 3.0% | 2,971 | 2,885 | 2,534 | 2,422 | 2,456 | 2,519 | 2,612 | 2,415 | 2,497 | 2,249 | 2,390 | 3,096 | 3,079 | 3,091 | 3,233 | 2,895 | 2,878 | 2,836 | 2,668 | 2,248 | 2,247 |
| Current Assets | 2.9% | 2,617 | 2,543 | 2,203 | 2,152 | 2,191 | 2,253 | 2,345 | 2,156 | 2,238 | 1,989 | 2,131 | 2,537 | 2,531 | 2,558 | 2,721 | 2,408 | 2,414 | 2,374 | 2,208 | 2,079 | 2,083 |
| Cash Equivalents | 37.5% | 425 | 309 | 276 | 315 | 522 | 543 | 869 | 633 | 565 | 414 | 398 | 633 | 530 | 486 | 683 | 248 | 273 | 376 | 279 | 480 | 805 |
| Inventory | 15.0% | 26.00 | 22.00 | 22.00 | 21.00 | 20.00 | 24.00 | 25.00 | 23.00 | 24.00 | 22.00 | 22.00 | 22.00 | 24.00 | 23.00 | 18.00 | 19.00 | 19.00 | 11.00 | 9.00 | 8.00 | - |
| Net PPE | 7.6% | 92.00 | 85.00 | 74.00 | 181 | 177 | 178 | 178 | 180 | 179 | 180 | 181 | 182 | 173 | 164 | 154 | 149 | 135 | 134 | 132 | 132 | 128 |
| Liabilities | 6.0% | 2,543 | 2,399 | 1,961 | 1,828 | 1,831 | 1,810 | 1,840 | 1,884 | 1,914 | 1,568 | 1,646 | 1,489 | 1,484 | 1,521 | 1,549 | 1,397 | 1,421 | 1,448 | 1,481 | 1,408 | 1,430 |
| Current Liabilities | 11.1% | 288 | 259 | 312 | 283 | 268 | 228 | 241 | 280 | 294 | 295 | 599 | 245 | 231 | 258 | 273 | 232 | 241 | 252 | 280 | 260 | 249 |
| Shareholder's Equity | -12.0% | 428 | 487 | 573 | 594 | 625 | 710 | 772 | 531 | 583 | 681 | 743 | 1,521 | 1,503 | 1,472 | 1,577 | 1,498 | 1,457 | 1,387 | 1,101 | 840 | 817 |
| Retained Earnings | -5.5% | -1,639 | -1,553 | -1,429 | -1,377 | -1,330 | -1,225 | -1,159 | -1,384 | -1,302 | -1,221 | -1,131 | -909 | -878 | -846 | -707 | -857 | -883 | -882 | -967 | -1,287 | -1,282 |
| Additional Paid-In Capital | 1.4% | 2,118 | 2,089 | 2,060 | 2,035 | 2,009 | 1,983 | 1,964 | 1,942 | 1,910 | 1,926 | 1,896 | 2,312 | 2,272 | 2,234 | 2,204 | 2,219 | 2,177 | 2,118 | 2,047 | 2,030 | 2,012 |
| Shares Outstanding | 0.1% | 143 | 143 | 142 | 142 | 142 | 142 | 141 | 141 | 141 | 141 | 140 | 140 | 139 | 139 | 140 | 141 | 140 | 139 | 138 | 137 | 129 |
| Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | 223 | 218 | 210 | 213 | 162 | 188 | 180 | 139 | 130 | 121 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -21.0% | -455 | -376 | -274 | 130 | 98.00 | 54.00 | 31.00 | -74.91 | -29.61 | -11.18 | 36.00 | 216 | 213 | 230 | 346 | 183 | 170 | 697 | 603 | 508 | 563 |
| Share Based Compensation | 2.0% | 103 | 101 | 100 | 97.00 | 104 | 109 | 121 | 193 | 209 | 227 | 230 | 170 | 148 | 142 | 147 | 146 | 156 | 148 | 131 | 120 | 106 |
| Cashflow From Investing | 24.2% | -227 | -300 | -262 | -379 | -73.77 | -171 | 195 | 288 | 268 | 448 | 274 | 225 | 124 | -66.11 | -41.27 | -505 | -814 | -1,079 | -929 | -657 | -500 |
| Cashflow From Financing | 32.0% | 586 | 444 | -55.29 | -66.77 | -67.14 | 246 | 246 | -213 | -203 | -509 | -596 | -55.90 | -80.01 | -53.94 | 100 | 90.00 | 112 | 530 | 476 | 470 | 610 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | 0.00 | 91.00 | 125 | 125 | 125 | 34.00 | - | - | - | - | - | - |
IONS Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Revenue | $ 188,411 | $ 133,791 | $ 318,935 | $ 275,710 |
| Expenses: | ||||
| Cost of sales | 2,537 | 4,745 | 3,880 | 8,914 |
| Research, development and patent | 229,927 | 180,758 | 427,740 | 341,884 |
| Selling, general and administrative | 46,142 | 33,802 | 91,658 | 67,929 |
| Total operating expenses | 278,606 | 219,305 | 523,278 | 418,727 |
| Loss from operations | (90,195) | (85,514) | (204,343) | (143,017) |
| Other income (expense): | ||||
| Investment income | 20,792 | 3,403 | 39,419 | 5,396 |
| Interest expense | (2,291) | (2,130) | (3,899) | (4,252) |
| Interest expense related to sale of future royalties | (17,655) | 0 | (33,170) | 0 |
| Gain (loss) on investments | 718 | (6,337) | 189 | (12,963) |
| Other income (expense) | 11,183 | (12,297) | 11,414 | (12,110) |
| Loss before income tax expense | (77,448) | (102,875) | (190,390) | (166,946) |
| Income tax expense | (7,842) | (2,260) | (19,223) | (3,354) |
| Net loss | $ (85,290) | $ (105,135) | $ (209,613) | $ (170,300) |
| Basic net loss per share (in dollars per share) | $ (0.6) | $ (0.74) | $ (1.47) | $ (1.2) |
| Diluted net loss per share (in dollars per share) | $ (0.6) | $ (0.74) | $ (1.47) | $ (1.2) |
| Shares used in computing basic net loss per share (in shares) | 143,098 | 141,794 | 142,918 | 141,697 |
| Shares used in computing diluted net loss per share (in shares) | 143,098 | 141,794 | 142,918 | 141,697 |
| Commercial Revenue [Member] | ||||
| Revenue: | ||||
| Revenue | $ 77,897 | $ 78,184 | $ 145,664 | $ 150,468 |
| SPINRAZA Royalties [Member] | ||||
| Revenue: | ||||
| Revenue | 61,012 | 59,627 | 111,258 | 113,444 |
| Other Commercial Revenue [Member] | ||||
| Revenue: | ||||
| Revenue | 16,885 | 18,557 | 34,406 | 37,024 |
| Research and Development Revenue [Member] | ||||
| Revenue: | ||||
| Revenue | 110,514 | 55,607 | 173,271 | 125,242 |
| Collaborative Agreement Revenue [Member] | ||||
| Revenue: | ||||
| Revenue | 91,013 | 38,247 | 129,347 | 88,032 |
| Eplontersen Joint Development Revenue [Member] | ||||
| Revenue: | ||||
| Revenue | $ 19,501 | $ 17,360 | $ 43,924 | $ 37,210 |
IONS Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 424,790 | $ 276,472 |
| Short-term investments | 1,960,598 | 1,710,397 |
| Contracts receivable | 27,956 | 25,538 |
| Inventories | 25,538 | 22,033 |
| Other current assets | 177,872 | 168,254 |
| Total current assets | 2,616,754 | 2,202,694 |
| Property, plant and equipment, net | 91,634 | 74,294 |
| Right-of-use assets | 176,718 | 181,544 |
| Deposits and other assets | 86,025 | 75,344 |
| Total assets | 2,971,131 | 2,533,876 |
| Current liabilities: | ||
| Accounts payable | 24,021 | 17,921 |
| Accrued compensation | 29,322 | 49,178 |
| Accrued liabilities | 104,745 | 140,101 |
| Income taxes payable | 24,732 | 6,249 |
| Current portion of deferred contract revenue | 96,252 | 90,577 |
| Other current liabilities | 8,903 | 7,535 |
| Total current liabilities | 287,975 | 311,561 |
| Long-term deferred contract revenue | 254,398 | 287,768 |
| Liability related to sale of future royalties, net | 510,174 | 0 |
| Long-term lease liabilities | 175,020 | 178,941 |
| Long-term obligations | 16,436 | 15,973 |
| Total liabilities | 2,542,830 | 1,960,989 |
| Stockholders' equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 143,167,414 and 142,057,736 shares issued and outstanding at June 30, 2023 (unaudited) and December 31, 2022, respectivel | 143 | 142 |
| Additional paid-in capital | 2,118,309 | 2,059,850 |
| Accumulated other comprehensive loss | (50,913) | (57,480) |
| Accumulated deficit | (1,639,238) | (1,429,625) |
| Total stockholders' equity | 428,301 | 572,887 |
| Total liabilities and stockholders' equity | 2,971,131 | 2,533,876 |
| 1.75 Percent Convertible Senior Notes [Member] | ||
| Current liabilities: | ||
| Convertible senior notes, net | 560,937 | 0 |
| 0 Percent Convertible Senior Notes [Member] | ||
| Current liabilities: | ||
| Convertible senior notes, net | 623,809 | 622,242 |
| 0.125 Percent Convertible Senior Notes [Member] | ||
| Current liabilities: | ||
| Convertible senior notes, net | $ 114,081 | $ 544,504 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.